Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

CC-115

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

BMS

Drug class:

mTOR inhibitor, DNA PK inhibitor

Related drugs:

encapsulated rapamycin (0)

inhibitors of the PI3K/AKT/mTOR pathway (0)

etidaligide (0)

everolimus (138)

temsirolimus (37)

PF-05212384 (31)

GSK2126458 (17)

PF-04691502 (6)

niclosamide (1)

rapamycin topical (0)

ridaforolimus (0)

encapsulated rapamycin (0)

inhibitors of the PI3K/AKT/mTOR pathway (0)

etidaligide (0)

›

PTEN mutation	Prostate Cancer	PTEN mutation	Prostate Cancer	enzalutamide + CC-115 Sensitive: C3 – Early Trials enzalutamide + CC-115 Sensitive : C3	enzalutamide + CC-115 Sensitive: C3 – Early Trials enzalutamide + CC-115 Sensitive : C3
PTEN deletion	Prostate Cancer	PTEN deletion	Prostate Cancer	enzalutamide + CC-115 Sensitive: C3 – Early Trials enzalutamide + CC-115 Sensitive : C3	enzalutamide + CC-115 Sensitive: C3 – Early Trials enzalutamide + CC-115 Sensitive : C3
PIK3CA mutation	Non Small Cell Lung Cancer	PIK3CA mutation	Non Small Cell Lung Cancer	CC-115 Sensitive: D – Preclinical CC-115 Sensitive : D	CC-115 Sensitive: D – Preclinical CC-115 Sensitive : D